Colonoscopic cancer detection rate: a new performance measure – is it FIT for purpose?
Authors:
- 9 December 2023
- journal article
- research article
- Published by BMJ in Frontline Gastroenterology
- Vol. 15 (3) , 198-202
Abstract
Introduction Gastrointestinal symptoms correlate poorly with cancer diagnosis. A faecal immunochemical test (FIT) result of ≥10 µg has high sensitivity and negative predictive value for colorectal cancer (CRC) detection. An FIT-based diagnostic pathway may lead to more effective resource utilisation. We aimed to use National Endoscopy Database (NED) data to create a new colonoscopy performance measure, cancer detection rate (CDR) to assess the appropriate identification of target populations for colonoscopy; then to use CDR to assess the impact of implementing an FIT-based referral pathway locally. Methods NED data were analysed to compare local diagnostic colonoscopic CDR in 2019 (prepathway revision) and 2021 (postpathway revision), benchmarked against overall national CDR for the same time frames. Results 1, 123, 624 NED diagnostic colonoscopies were analysed. Locally, there was a significant increase in CDR between 2019 and 2021, from 3.01% (2.45%–3.47%) to 4.32% (3.69%–4.95%), p=0.003. The CDR increase was due to both a 10% increase in the number of CRCs detected and a 25% reduction in the number of diagnostic colonoscopies performed. Nationally, there was a smaller, but significant, increase in CDR from 2.02% (1.99%–2.07%) to 2.33% (2.29%–2.37%), pConclusion Our study indicates that the introduction of a robustly vetted FIT-based algorithm to determine whether diagnostic colonoscopy is required, is effective in increasing the colonoscopic CDR. Moreover, CDR appears to be a meaningful performance metric that can be automatically calculated through NED, enabling monitoring of the quality of referral and vetting pathways.Keywords
This publication has 7 references indexed in Scilit:
- FIT for colonoscopy: Benefits of the faecal immunochemical test for triaging symptomatic patientsThe Lancet Regional Health - Europe, 2022
- Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG)Gut, 2022
- Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based studyThe Lancet Gastroenterology & Hepatology, 2021
- Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy studyGut, 2020
- Development of a national automated endoscopy database: The United Kingdom National Endoscopy Database (NED)United European Gastroenterology Journal, 2019
- Application of NICE guideline NG12 to the initial assessment of patients with lower gastrointestinal symptoms: not FIT for purpose?Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2017
- Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysisBMJ, 2010